Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience-Reference-Cited by-同舟云学术

Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience

Published:2022-11-09 Issue:1 Volume:46 Page:65-75
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Oosterhuis Ingrid^ORCID,Scholl Joep^ORCID,van Puijenbroek Eugène^ORCID,Kant Agnes^ORCID,van Hunsel Florence^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-022-01253-5.pdf

Reference50 articles.

1. European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. 2020. https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu. Accessed 18 Feb 2022.

2. European Medicines Agency. SmPC Comirnaty. 2021. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf. Accessed 14 July 2022.

3. European Medicines Agency. SmPC Spikevax. 2021. https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf. Accessed 14 July 2022.

4. European Medicines Agency. SmPC Vaxzevria 2021. https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf. Accessed 14 July 2022.

5. European Medicines Agency. SmPC Covid-19 vaccine Janssen. 2021. https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf. Accessed 14 July 2021.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects;Current Pharmaceutical Biotechnology;2024-10

2. Menstrual disorders following COVID-19 vaccination: a review using a systematic search;Frontiers in Drug Safety and Regulation;2024-01-31

3. Patient and Public Involvement in Pharmacovigilance;Principles and Practice of Pharmacovigilance and Drug Safety;2024

4. Menstrual abnormalities after COVID‐19 vaccination in the Netherlands: A description of spontaneous and longitudinal patient‐reported data;British Journal of Clinical Pharmacology;2023-06-25

5. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands;Vaccine;2023-06